After years of production problems and perpetual shortages, Sanofi Pasteur will stop production of bladder cancer vaccine TheraCys BCG Live attenuated, saying it has been unable to find another ...

Amid a global drug shortage, thousands of patients with bladder cancer are unable to receive their recommended treatment each year. While Merck has pledged to make as many doses as it can, the company ...

Sanofi SA plans to stop producing a bladder-cancer treatment that was in short supply for several years, saying it hasn’t been able to restore full production at a Toronto manufacturing plant that had ...

Sanofi Pasteur said it’s discontinuing the manufacture of TheraCys, an important bladder cancer drug, and shortages are expected, while the US Food and Drug Administration (FDA) on Friday released ...

If you or a loved one has been diagnosed with BCG-unresponsive non-muscle invasive bladder cancer and are exploring your ...